graphic
abstract
highlight
describ
cooper
neutral
vivo
protect
cooper
turn
nonneutr
ebolaviru
antibodi
potent
neutral
hotspot
antibodi
cooper
identifi
ebola
viru
glycoprotein
brief
howel
et
al
describ
phenomenon
enabl
cooper
neutral
weakli
neutral
andor
nonneutr
ebolaviru
monoclon
antibodi
exhibit
potent
neutral
combin
previous
identifi
antibodi
nonprotect
alon
offer
protect
ebola
sudan
viru
challeng
mice
combin
drug
combin
synergist
combin
efficaci
exce
sum
individu
action
rare
includ
ineffect
drug
becom
effect
combin
identifi
sever
enabl
pair
neutral
nonneutr
antiebolaviru
monoclon
antibodi
whose
combin
exhibit
new
function
profil
includ
transform
nonneutr
antibodi
neutral
subneutr
concentr
antibodi
enabl
nonneutr
antibodi
ic
mm
exhibit
potent
neutral
ic
nm
alon
fail
protect
ebolavirusinfect
mice
combin
two
antibodi
provid
protect
furthermor
nonneutr
exponenti
enhanc
potenc
two
neutral
antibodi
ebola
sudan
virus
identifi
hotspot
bind
enabl
antibodi
pair
near
interfac
glycan
cap
enabl
cooper
may
underappreci
phenomenon
virus
implic
design
develop
immunotherapeut
vaccin
ebola
viru
ebov
diseas
evd
epidem
claim
live
underscor
need
effect
therapeut
deadli
viru
member
famili
filovirida
caus
human
outbreak
pastsudan
viru
sudv
bundibugyo
viru
bdbv
marburg
viru
marv
rougeron
et
al
monoclon
antibodi
mab
target
filoviru
glycoprotein
gp
among
promis
countermeasur
filovirus
sever
studi
shown
superior
specif
combin
mab
target
differ
ebov
gp
epitop
compar
monotherapi
oling
et
al
pettitt
et
al
qiu
et
al
qiu
et
al
qiu
et
al
combin
antibodi
therapi
adenovirusexpress
interferon
ifn
nonhuman
primat
nhp
also
result
enhanc
efficaci
qiu
et
al
studi
focus
ebovspecif
therapi
recent
target
ebolavirus
demonstr
improv
neutral
efficaci
combin
sever
panebolaviru
therapeut
mab
holtsberg
et
al
howel
et
al
keck
et
al
find
indic
engag
multipl
antibodi
differ
protect
mechan
highli
effect
control
filoviru
infect
filoviru
surfac
glycoprotein
gp
consist
disulfidelink
subunit
crystal
structur
ebov
gp
complex
neutral
mab
show
three
subunit
assembl
chalicelik
structur
surround
three
subunit
ntermin
portion
form
base
chalic
lee
et
al
anchor
gp
viru
membran
endosom
receptor
bind
site
rb
posit
apex
core
larg
conceal
glycan
cap
rim
chalic
highli
glycosyl
disord
mucinlik
domain
mld
bestcharacter
neutral
epitop
within
ebov
gp
socal
base
epitop
consist
residu
within
recogn
mab
davidson
et
al
lee
et
al
zmapp
therapeut
mab
cocktail
compon
davidson
et
al
murin
et
al
pallesen
et
al
tran
et
al
recent
other
identifi
number
neutral
epitop
within
rb
flyak
et
al
howel
et
al
misasi
et
al
glycan
cap
bornholdt
et
al
flyak
et
al
holtsberg
et
al
intern
fusion
loop
bornholdt
et
al
misasi
et
al
number
studi
identifi
synergist
pair
neutral
mab
target
hiv
li
et
al
mascola
et
al
miglietta
et
al
pollara
et
al
vijhwarri
et
al
sever
acut
respiratori
syndrom
sar
coronaviru
ter
meulen
et
al
hepat
c
viru
carlsen
et
al
exampl
synergi
observ
two
antibodi
could
neutral
viru
independ
describ
novel
phenomenon
cooper
neutral
mab
pair
consist
neutral
mab
nonneutr
mab
identifi
sever
pair
screen
panel
mab
bind
ebolaviru
glycoprotein
abil
neutral
one
ebolavirus
observ
neutral
weakli
moder
neutral
mab
enhanc
pair
specif
nonneutr
mab
target
epitop
within
glycan
cap
ebolaviru
gp
also
found
otherwis
nonneutr
panebolaviru
mab
acquir
neutral
activ
presenc
subneutr
concentr
mab
bound
adjac
epitop
final
demonstr
cooper
activ
extend
protect
vivo
pair
mab
individu
nonprotect
provid
full
protect
ebov
infect
combin
cocktail
first
evalu
potenti
competit
variou
mab
bind
ebov
gp
use
elisabas
assay
elisa
shown
elisa
bind
curv
mab
e
g
h
b
c
f
gpdtm
ebov
ad
sudv
e
f
bdbv
g
restv
h
presenc
fix
concentr
mgml
ch
b
comparison
mgml
irrelev
mab
black
data
point
repres
averag
three
measur
see
also
tabl
plate
coat
ebov
gp
preincub
satur
concentr
individu
ebovspecif
mab
panebolaviru
mab
holtsberg
et
al
keck
et
al
nonbind
neg
control
mab
test
mab
biotinyl
mous
fc
region
ad
ec
concentr
rel
bind
determin
note
competit
mab
close
locat
epitop
tabl
exampl
mab
describ
keck
et
al
among
gp
basebind
mab
consist
previou
report
murin
et
al
interestingli
studi
reveal
preincub
macaquederiv
mab
enhanc
bind
respect
decreas
bind
addit
whose
epitop
overlap
keck
et
al
also
enhanc
bind
bound
first
gp
bind
enhanc
nearli
sinc
mab
test
exhibit
panebolaviru
reactiv
includ
holtsberg
et
al
keck
et
al
also
assay
enhanc
mab
bind
sudv
gp
observ
modest
increas
bind
sudv
gp
presenc
higher
higher
tabl
mab
glycan
cap
binder
primarili
ebov
reactiv
also
bind
weakli
sudv
gp
bind
sudv
enhanc
respect
tabl
test
bind
enhanc
full
rang
mab
concentr
bind
ebov
gp
strongli
increas
presenc
satur
concentr
bind
presenc
satur
concentr
reduct
ec
respect
figur
similar
lesser
increas
bind
observ
ebov
gp
presenc
reduct
ec
figur
bind
figur
bind
sudv
gp
enhanc
presenc
figur
enhanc
weak
bind
sudv
gp
observ
figur
also
slightli
enhanc
bind
bdbv
gp
figur
restv
gp
figur
result
thu
demonstr
multipl
combin
mab
enhanc
bind
ebov
sudv
andor
bdbv
next
determin
whether
enhanc
bind
also
extend
abil
mab
neutral
ebov
similar
matrix
array
enhanc
experi
perform
ebov
neutral
use
pseudotyp
vesicular
stomat
viru
vsv
vsvebov
gpluc
infect
vero
cell
mab
appli
respect
ec
concentr
abil
neutral
determin
absenc
presenc
individu
nonneutr
antibodi
satur
concentr
consist
mab
bind
studi
neutral
potenti
presenc
moder
increas
increas
figur
gp
basebind
mab
moder
enhanc
also
observ
presenc
mab
test
impact
neutral
contrast
anoth
basebind
mab
neutral
presenc
test
mab
remain
within
valu
seen
alon
neutral
slightli
potenti
presenc
respect
significantli
reduc
presenc
consist
overlap
bind
footprint
two
mab
ebov
gp
howel
et
al
keck
et
al
examin
potenti
cooper
neutral
one
mab
wide
concentr
rang
presenc
second
nonneutr
mab
constant
satur
concentr
mgml
neutral
mab
subneutr
concentr
show
poor
neutral
vsvebov
gpluc
ic
mgml
neutral
potenc
dramat
augment
reduct
ic
presenc
figur
revers
experi
nonneutr
exhibit
strong
dosedepend
neutral
presenc
subneutr
concentr
figur
figur
also
test
determin
whether
cooper
shown
neutral
ebov
also
appli
neutral
sudv
strongli
neutral
vsvsudv
gpluc
neutral
weakli
combin
two
mab
gave
neutral
pattern
suggest
mere
addit
improv
figur
indic
potenti
specif
ebov
antisudv
antibodi
bind
region
within
sudv
gp
dia
et
al
homolog
base
epitop
ebov
gp
target
sinc
observ
enhanc
neutral
ebov
examin
whether
would
also
enhanc
neutral
sudv
presenc
mgml
strong
left
shift
observ
neutral
doserespons
curv
figur
neutral
ic
reduc
mgml
mgml
presenc
mgml
respect
interestingli
neutral
activ
also
potenti
presenc
fusion
loopbind
mab
figur
combin
also
test
use
plaqu
reduct
neutral
prnt
assay
live
ebov
sudv
biosafeti
level
contain
fail
neutral
ebov
concentr
mgml
weakli
neutral
neutral
mgml
figur
howev
presenc
fix
concentr
mgml
show
potent
ebov
neutral
activ
ic
mgml
figur
sudv
effect
neutral
alon
addit
affect
neutral
potenc
confirm
cooper
specif
ebov
figur
extent
mab
synergi
describ
quantifi
compusyn
softwar
use
mathemat
approach
develop
chou
talalay
quantifi
synergi
chou
chou
talalay
methodolog
defin
two
parametersth
combin
index
ci
dose
reduct
index
dri
describ
effect
drug
combin
ci
provid
quantit
measur
addit
effect
ci
synerg
ci
antagon
ci
dri
provid
measur
potenti
fold
dose
reduct
achiev
drug
combin
ci
dri
valu
calcul
ebov
neutral
full
rang
mab
concentr
figur
along
valu
neutral
fraction
affect
fa
fa
figur
analysi
reveal
extrem
high
degre
synergi
mab
pair
first
mab
pair
test
variou
concentr
second
kept
constant
concentr
figur
concentrationdepend
ci
valu
rang
dri
valu
rang
respect
figur
sudv
neutral
degre
synergi
margin
ci
close
figur
clear
synergi
evid
combin
ci
low
figur
pair
analysi
confirm
synergist
neutral
live
ebov
ci
valu
low
dri
valu
high
figur
margin
neutral
enhanc
live
sudv
ci
valu
mostli
around
dri
valu
figur
also
test
synergi
found
combin
exhibit
margin
synergi
ci
dri
higher
concentr
figur
howev
result
synergi
b
titrat
fix
subneutr
concentr
mgml
red
show
enhanc
potenc
compar
alon
blue
mgml
dot
line
c
titrat
mgml
show
clear
neutral
dose
respons
red
contrast
alon
blue
dot
line
show
percentag
neutral
mgml
alon
neutral
vsvsudvgpluc
alon
green
blue
show
dosedepend
neutral
viru
combin
red
appear
mere
addit
e
neutral
alon
orang
presenc
mgml
blue
mgml
red
potenti
compar
alon
mgml
dot
line
f
potenti
also
seen
titrat
mgml
red
compar
neutral
alon
orang
g
h
prnt
assay
perform
use
live
ebov
g
sudv
h
treat
variou
concentr
blue
green
presenc
mgml
red
use
control
panebolaviru
antibodi
ci
valu
shown
indic
combin
neutral
fa
fraction
affect
antibodi
use
constant
variabl
concentr
viru
use
respect
neutral
assay
shown
x
axi
h
data
point
repres
averag
three
measur
sd
see
also
figur
evid
lower
concentr
ci
dri
concentr
mgml
figur
determin
whether
observ
mab
synergi
depend
either
bival
bind
fc
portion
mab
gener
purifi
fab
fragment
follow
digest
papain
ficin
fab
bound
readili
ebov
gp
lower
level
compar
full
immunoglobulin
g
igg
figur
fab
fulllength
figur
display
neutral
vsvebov
gpluc
exhibit
dosedepend
neutral
presenc
constant
concentr
figur
suggest
cooper
neutral
independ
bival
bind
mab
fc
region
bind
fab
ebov
gp
drastic
reduc
compar
fulllength
figur
slightli
enhanc
presenc
fab
full
igg
figur
consist
low
bind
fab
induc
margin
neutral
mgml
neutral
moder
enhanc
figur
sudv
fab
show
moder
neutral
vsvsudv
gpluc
strongli
enhanc
presenc
taken
togeth
data
indic
bival
bind
fc
portion
play
critic
role
observ
cooper
neutral
nevertheless
bival
configur
fulllength
mab
like
import
bind
ebov
epitop
suffici
avid
support
maxim
cooper
neutral
sinc
mab
demonstr
strongest
neutral
cooper
identifi
epitop
target
two
glycan
capbind
mab
previous
shown
use
overlap
peptid
competit
experi
bind
linear
epitop
within
partial
disord
loop
ebov
gp
glycan
cap
keck
et
al
bind
conform
epitop
involv
glycan
cap
holtsberg
et
al
defin
epitop
employ
shotgun
mutagenesi
construct
alascan
librari
ebov
gp
target
gp
residu
individu
mutat
davidson
et
al
cell
transfect
entir
librari
array
format
bind
mab
clone
evalu
highthroughput
flow
cytometri
epitop
map
identifi
ebov
gp
residu
within
core
within
glycan
cap
critic
bind
figur
alanin
substitut
residu
reduc
bind
wildtyp
respect
suggest
residu
constitut
key
contact
site
figur
contrast
show
reduct
bind
mutant
rel
wildtyp
gp
fact
exhibit
higher
bind
wildtyp
gp
similar
analysi
show
mutat
within
loop
essenti
elimin
bind
gp
wildtyp
reactiv
respect
figur
interestingli
loop
mutat
elimin
bind
increas
bind
figur
suggest
interact
two
epitop
addit
observ
alanin
substitut
adjac
epitop
residu
increas
bind
figur
key
residu
epitop
within
glycan
cap
within
core
lie
close
proxim
outer
side
adjac
partial
disord
loop
residu
lee
et
al
zhao
et
al
contain
epitop
describ
figur
avail
ebov
gp
structur
loop
partial
mask
epitop
key
contact
residu
posit
bottom
loop
interact
residu
lie
fusion
loop
base
epitop
figur
well
residu
near
interfac
mutat
juxtapos
may
remov
constraint
loop
allow
better
interact
consist
notion
substitut
also
led
increas
bind
nearli
figur
mutat
sever
residu
region
includ
disulfid
bond
cystein
also
significantli
increas
bind
figur
data
suggest
interplay
epitop
possibl
constrain
interact
adjac
residu
base
bind
data
hypothes
mutat
impair
bind
would
mimic
enhanc
effect
bind
neutral
activ
test
hypothesi
gener
mutant
gp
three
mutat
ebovgpaaa
ebovgpaaa
fail
bind
exhibit
moder
enhanc
bind
higher
wildtyp
wt
gp
figur
despit
moder
effect
tripl
mutat
bind
pseudotyp
vsv
viru
incorpor
tripl
mutat
vsvebov
gpaaaluc
neutral
effect
wildtyp
vsvebov
gpluc
figur
contrast
tripl
mutat
caus
modest
reduct
neutral
compar
wildtyp
vsvebov
gpluc
figur
indic
enhanc
neutral
specif
data
strongli
suggest
wildtyp
loop
inhibit
neutral
activ
mask
epitop
epitop
unmask
bind
loop
mab
displac
loop
mutat
reduct
albeit
modest
neutral
activ
vsvebov
gpaaa
may
also
relat
displac
loop
propos
make
contact
residu
loop
lee
et
al
understand
relationship
synergist
epitop
conduct
neg
stain
em
ebov
gp
complex
fab
alon
combin
refer
free
class
averag
show
bind
similar
region
gp
distinct
angl
approach
figur
data
consist
fab
bind
flexibl
loop
glycan
cap
bind
adjac
epitop
possibl
antibodi
bind
concurr
protom
figur
result
agre
alanin
scan
map
identifi
epitop
loop
epitop
residu
within
glycan
cap
partial
occlud
loop
despit
clear
fab
densiti
class
averag
abl
obtain
reconstruct
like
due
high
flexibl
antibodi
bound
epitop
determin
whether
observ
synergi
mab
neutral
vitro
would
translat
vivo
protect
test
efficaci
combin
stringent
mous
model
ebov
infect
use
singl
intraperiton
inject
antibodi
day
postinfect
dpi
first
studi
mice
treat
either
mgkg
individu
mab
mgkg
combin
regimen
mice
treat
exhibit
surviv
mice
nine
ten
control
mice
die
within
dpi
figur
level
protect
afford
signific
comparison
treatment
group
p
determin
logrank
mantelcox
test
contrast
mice
treat
combin
cocktail
two
mab
surviv
challeng
figur
protect
provid
cocktail
highli
signific
compar
individu
mab
control
p
mice
receiv
cocktail
also
develop
sever
diseas
evid
health
score
lack
weight
loss
figur
sinc
lower
dose
individu
mab
use
cocktail
exclud
unlik
possibl
mab
alon
would
protect
lower
dose
followup
studi
mab
use
mgkg
cocktail
monotherapi
keep
total
antibodi
dose
mg
addit
control
igg
monotherapi
arm
experi
confirm
mab
individu
protect
low
dose
mice
treat
mgkg
either
alon
show
surviv
respect
mice
treat
cocktail
surviv
challeng
p
figur
previous
shown
alon
mgkg
gave
partial
protect
sudv
infect
ifnr
mice
administ
three
time
start
hr
infect
repeat
dpi
holtsberg
et
al
shotgun
mutagenesi
librari
construct
ebov
gp
amino
acid
individu
mutat
alanin
reactiv
bind
mutant
evalu
compar
control
mab
b
residu
mutat
bind
reduc
compar
wildtyp
mutat
decreas
light
gray
black
bind
error
bar
repres
averag
three
measur
sd
c
reactiv
bind
mutant
evalu
compar
control
mab
mutat
residu
reduc
bind
compar
wildtyp
significantli
reduc
dark
gray
light
gray
bind
e
cartoon
represent
epitop
circl
lie
adjac
bind
site
red
ebov
gp
structur
pdb
magnifi
section
show
residu
involv
bind
interact
orang
f
graph
highlight
invers
relationship
red
bar
black
bar
bind
sever
mutant
within
respect
epitop
particular
dramat
impair
bind
increas
bind
compar
wildtyp
contrast
mutant
reduc
bind
enhanc
bind
show
enhanc
bind
mutant
g
residu
adjac
residu
mutat
bind
gp
increas
use
model
test
postexposur
efficaci
cocktail
mice
receiv
mgkg
dpi
n
fulli
protect
sudv
infect
five
six
control
anim
succumb
infect
figur
howev
contrast
ebov
studi
sudvinfect
mice
treat
cocktail
exhibit
sever
transient
sign
diseas
weight
loss
recoveri
figur
studi
describ
novel
phenomenon
function
cooper
mab
target
ebolaviru
glycoprotein
specif
identifi
two
adjac
epitop
within
ebov
gp
glycan
cap
bound
facilit
cooper
neutral
furthermor
observ
similar
phenomenon
anoth
set
mab
neutral
sudv
data
demonstr
cooper
neutral
exist
sever
ebolavirusspecif
antibodi
pair
identifi
previous
unknown
mechan
antibodi
target
virus
sinc
potenti
effect
nonneutr
antibodi
rare
ever
evalu
concert
neutral
antibodi
synergist
neutral
describ
sever
mab
target
hiv
laal
et
al
li
et
al
mascola
et
al
vijhwarri
et
al
xu
et
al
includ
tripl
quadrupl
combin
mab
li
et
al
mab
neutral
use
singli
combin
led
ci
valu
low
dri
valu
high
tripl
mab
cocktail
li
et
al
synergist
combin
hiv
antibodi
reach
ci
dri
potent
combin
vijhwarri
et
al
data
present
reminisc
report
synergi
among
hiv
antibodi
uniqu
aspect
find
identif
nonneutr
antibodi
convert
poorli
neutral
antibodi
potent
neutral
almost
ebov
neutral
activ
combin
poorli
neutral
mab
show
reduct
neutral
ic
cocktail
exhibit
ci
low
dri
high
presenc
suboptim
concentr
gp
base
binder
behav
neutral
mab
satur
doserespons
curv
similarli
show
poorli
neutral
sudv
nonneutr
mab
strongli
potenti
neutral
activ
sudvspecif
mab
dramat
effect
mab
combin
extrem
high
dri
low
ci
fact
combin
result
qualit
differ
obtain
individu
mab
transform
nonneutr
neutral
refer
phenomenon
enabl
cooper
neutral
ie
effect
neutral
depend
mab
one
mab
nonneutr
observ
mab
cooper
may
relat
trigger
induc
epitop
ie
epitop
either
form
expos
upon
bind
gp
anoth
antibodi
may
caus
conform
chang
lead
better
access
respect
epitop
extens
interact
loop
core
region
close
base
epitop
suggest
loopbind
antibodi
may
peel
loop
main
gp
bodi
allow
effect
neutral
gp
base
mab
consist
hypothesi
em
data
suggest
loop
bound
flexibl
appear
side
gp
trimer
notion
also
consist
observ
competit
sinc
appear
make
contact
loop
displac
loop
would
expect
reduc
bind
contrast
show
cooper
bind
gp
base
epitop
sharper
angl
murin
et
al
suggest
may
contact
loop
despit
allur
model
cooper
neutral
least
explain
entir
increas
epitop
exposur
subsequ
mutual
bind
enhanc
combin
cocktail
increas
reciproc
bind
individu
mab
valu
yet
result
enhanc
neutral
ci
valu
similarli
combin
result
modest
bind
enhanc
otherwis
nonneutr
acquir
qualit
novel
properti
strong
neutral
potenc
similar
potent
ebov
neutral
qualit
distinct
abil
mab
combin
neutral
ebov
may
result
combin
bind
enhanc
cooper
function
level
mechan
remain
determin
limit
bind
studi
present
perform
absenc
viru
target
cell
neutral
occur
possibl
bind
enhanc
actual
greater
viru
bind
cellular
attach
factor
due
conform
chang
may
trigger
cooper
interact
gp
factor
antibodi
strike
highest
degre
cooper
observ
mab
adjac
epitop
enhanc
neutral
may
result
two
mab
give
effici
occup
mask
critic
region
glycoprotein
compar
provid
singl
mab
differ
mechan
mutual
exclus
may
contribut
observ
function
cooper
data
present
signific
implic
immunotherapi
vaccin
develop
enabl
cooper
neutral
virus
specif
mab
may
feasibl
varieti
viral
pathogen
readili
discov
use
matrix
neutral
assay
describ
use
two
synergist
mab
therapeut
rather
combin
antibodi
addit
effect
may
significantli
reduc
dose
requir
effect
treatment
viral
infect
overcom
major
impedi
develop
antiinfect
antibodi
therapi
howev
least
treatment
chronic
infect
caveat
approach
vulner
viral
escap
escap
one
antibodi
may
render
cocktail
ineffect
find
could
also
implic
vaccin
design
could
exploit
promot
cooper
epitopespecif
antigen
resurfac
filoviru
protein
produc
purifi
previous
describ
keck
et
al
howel
et
al
briefli
code
region
ebov
gpdtm
sudv
gpdtm
insert
baculoviru
transfer
vector
pfastbac
invitrogen
use
transfect
insect
cell
recombin
baculovirus
contain
gpdtm
recov
supernat
amplifi
cell
final
viru
use
infect
cell
protein
lefthand
panel
show
ebola
gp
trimer
volum
map
crystal
structur
protom
ebov
gpdmuc
superimpos
onto
repres
class
averag
c
righthand
panel
volum
map
remov
highlight
fabgp
interact
antibodi
appear
bind
flexibl
epitop
within
proxim
glycan
cap
dark
blue
purifi
supernat
dpi
supernat
concentr
mix
ni
sepharos
fast
flow
bead
ge
life
scienc
overnight
c
next
day
bead
separ
centrifug
pack
biorad
econo
column
column
wash
pb
glycerol
tween
mm
imidazol
protein
elut
buffer
contain
mm
imidazol
dialyz
pb
contain
glycerol
arginin
glutam
acid
protein
analyz
sdspage
western
blot
puriti
protein
concentr
determin
use
bicinchonin
acid
bca
assay
protein
aliquot
store
c
longterm
storag
antibodi
produc
cell
express
appropri
igh
igl
follow
transfect
express
plasmid
use
polyethylen
amin
polysci
antibodi
purifi
cultur
supernat
use
protein
chromatographi
column
previous
describ
keck
et
al
howel
et
al
mab
gener
n
benthamiana
plant
genet
modifi
produc
homogen
mammalian
nglycan
gngn
glycoform
plant
grown
week
enclos
growth
room
c
express
vector
igh
igl
introduc
vacuum
infiltr
describ
day
mab
extract
leaf
tissu
purifi
protein
chromatographi
endotoxin
remov
use
acrodisc
unit
mustang
q
membran
pall
life
scienc
mous
mab
produc
purifi
previous
describ
holtsberg
et
al
fab
version
mab
gener
use
pierc
fab
kit
pierc
mous
fab
kit
thermo
fisher
scientif
accord
manufactur
protocol
briefli
digest
agarosebound
papain
hr
c
purif
protein
column
chromatographi
remov
undigest
igg
fc
reaction
unbound
fraction
contain
fab
dialyz
overnight
pb
c
analysi
nonreduc
sdspage
fab
gener
manner
except
mab
digest
perform
use
ficinbound
agaros
mm
cystein
antigen
dilut
mgml
dulbecco
phosphatebuff
salin
dpb
coat
onto
nunc
maxisorb
plate
thermo
fisher
scientif
incub
overnight
c
next
day
plate
wash
dpb
tween
ad
block
buffer
hr
room
temperatur
block
irrelev
control
igg
ad
well
mgml
min
ad
concentr
rang
detect
antibodi
min
antibodi
bound
plate
wash
secondari
antibodi
either
antimous
antihuman
ad
hr
room
temperatur
hr
plate
wash
ml
tmb
substrat
ad
min
read
nm
softmax
use
collect
data
data
analyz
prism
fit
fourparamet
logist
curv
vsvebov
gpluc
vsvsudv
gp
luc
vsvebov
gpaaa
luc
pseudotyp
virus
gener
previous
describ
keck
et
al
howel
et
al
briefli
glycoprotein
plasmid
transfect
cell
dmem
supplement
fetal
bovin
serum
fb
penicillinstreptomycin
ps
overnight
infect
cell
maebov
challeng
mice
treat
dpi
mgkg
alon
green
alon
blue
combin
mgkg
antibodi
red
b
maebov
challeng
mice
treat
dpi
lower
dose
mgkg
control
igg
green
control
igg
blue
dose
level
red
c
sudvchalleng
mice
treat
combin
mgkg
day
postinfect
vsvdg
moi
serumfre
dmem
hr
hr
infect
cell
wash
three
time
dpb
exchang
media
dmem
supplement
fb
ps
allow
viru
propag
overnight
supernat
contain
viru
collect
centrifug
rpm
min
clarifi
aliquot
store
c
plaqu
assay
perform
obtain
viral
titer
vero
cell
atcc
cultur
eagl
minimum
essenti
medium
emem
supplement
fb
ps
c
co
cell
seed
cellswel
black
flatbottom
tissu
cultur
plate
follow
day
antibodi
dilut
serumfre
emem
supplement
ps
mix
vesicular
stomat
viru
lack
g
protein
express
appropri
filoviru
gp
vsvgp
ebov
sudv
ebov
gpaaa
room
temperatur
hr
ml
viru
antibodi
ad
plate
vero
cell
moi
plate
incub
hr
c
addit
ml
emem
supplement
fb
ps
overnight
incub
next
day
media
viru
remov
plate
ad
ml
passiv
cell
lysi
buffer
promega
cell
allow
lyse
min
room
temper
addit
ml
luciferas
activ
reagent
promega
luminesc
read
immedi
biomek
plate
reader
data
fit
curv
use
prism
graphpad
softwar
percent
neutral
calcul
base
well
contain
viru
without
antibodi
mab
combin
control
mab
ad
indic
concentr
plaqueform
unit
pfu
ebov
sudv
bonifac
c
co
hr
viru
antibodi
mixtur
ad
vero
cell
overlaid
agaros
seakem
one
part
eagl
basal
medium
ebm
contain
mm
hepe
fb
second
overlay
neutral
red
ad
day
later
incub
anoth
hr
count
plaqu
shotgun
mutagenesi
perform
previous
describ
howel
et
al
briefli
librari
contain
ebov
gp
mayinga
residu
mutat
alanin
gener
transfect
cell
plate
cell
express
gp
mutant
incub
primari
antibodi
secondari
antibodi
bind
detect
use
intellicyt
highthroughput
flow
cytomet
intellicyt
background
subtract
control
well
rel
bind
mutant
compar
wildtyp
control
mutant
identifi
critic
lost
bind
test
antibodi
intern
control
davidson
doranz
mutat
introduc
ebov
gpdtm
pcagg
vector
protein
express
purifi
describ
wildtyp
protein
compar
bind
profil
wildtyp
ebov
gp
ebov
gpaaa
mutant
ngwell
wildtyp
mutant
protein
coat
nunc
maxisorb
plate
overnight
c
next
day
plate
wash
dpb
tween
block
ml
block
buffer
hr
room
temperatur
block
buffer
wash
addit
antibodi
allow
bind
hr
room
temperatur
secondari
antihuman
antimous
ad
detect
mab
bind
hr
room
temperatur
plate
wash
ml
tmb
ad
min
read
versamax
plate
reader
nm
data
fit
curv
use
graphpad
prism
igg
digest
fab
incub
papain
hr
c
subsequ
purifi
use
protein
column
follow
column
ge
healthcar
molar
excess
fab
ad
ebov
gpdmuc
incub
overnight
c
complex
purifi
sec
column
pipet
onto
carbon
cover
copper
mesh
grid
neg
stain
uranyl
format
grid
imag
technai
spirit
kev
tietz
complementari
metal
oxid
semiconductor
cmo
camera
data
collect
set
magnif
nomin
defocu
mm
oper
leginon
suloway
et
al
use
appion
lander
et
al
micrograph
process
dogpick
sort
class
averag
xmipp
sorzano
et
al
isol
fab
unrecogniz
class
remov
final
class
gener
show
differ
view
complex
interpret
data
figur
done
use
ucsf
chimera
goddard
et
al
mous
challeng
studi
ebov
femal
balbc
mice
week
age
purchas
charl
river
laboratori
mice
challeng
intraperiton
ip
pfu
mouseadapt
ebov
mayinga
strain
maebov
dpi
mice
treat
indic
mab
pb
ip
rout
mice
observ
minimum
per
day
pan
weight
clinic
sign
diseas
record
day
observ
increas
minimum
twice
daili
upon
onset
clinic
sign
diseas
moribund
surviv
mice
human
euthan
basi
institut
anim
care
use
committe
iacuc
approv
criteria
mice
observ
minimum
day
exposur
mous
challeng
studi
sudv
ifnar
mice
age
week
background
purchas
jackson
laboratori
mice
challeng
ip
pfu
sudv
treat
dpi
indic
antibodi
ip
inject
mice
observ
daili
lethal
clinic
sign
diseas
day
moribund
surviv
mice
human
euthan
basi
iacucapprov
criteria
ethic
statement
anim
research
use
mice
conduct
protocol
approv
us
armi
medic
research
institut
infecti
diseas
usamriid
institut
anim
care
use
committe
iacuc
complianc
anim
welfar
act
feder
statut
regul
relat
anim
experi
involv
anim
usamriid
facil
fulli
accredit
associ
assess
accredit
laboratori
anim
care
intern
adher
principl
state
guid
care
use
laboratori
anim
nation
research
council
supplement
inform
includ
three
figur
two
tabl
found
articl
onlin
http
mja
founder
sharehold
integr
biotherapeut
fwh
ss
hv
stock
option
integr
biotherapeut
bjd
founder
sharehold
integr
molecular
opinion
conclus
interpret
recommend
author
necessarili
endors
us
armi
mention
trade
name
commerci
product
constitut
endors
recommend
use
depart
armi
depart
defens
